ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Birmingham, AL, USA:

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 125 other locations

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or...

Not yet enrolling
Ovarian Cancer
Drug: olaparibp, embro
Drug: Carboplatin

Phase 2

The University of Alabama at Birmingham
The University of Alabama at Birmingham

Birmingham, Alabama, United States

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...

Active, not recruiting
Recurrent Ovarian Cancer
Recurrent Primary Peritoneal Carcinoma
Drug: Relacorilant, 100mg QD
Drug: Relacorilant, 150mg QD

Phase 2

Corcept Therapeutics
Corcept Therapeutics

Birmingham, Alabama, United States and 20 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Biological: Nemvaleukin

Phase 3

Mural Oncology

Birmingham, Alabama, United States and 131 other locations

within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single ...

Enrolling
Ovarian Neoplasms
Drug: Niraparib
Drug: Paclitaxel

Phase 1, Phase 2

Tesaro
Tesaro

Birmingham, Alabama, United States and 24 other locations

of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

Phase 2

ImmunoGen
ImmunoGen

Birmingham, Alabama, United States and 77 other locations

of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Birmingham, Alabama, United States and 49 other locations

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus...

Active, not recruiting
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Biological: IMNN-001
Drug: Carboplatin

Phase 1, Phase 2

IMUNON
IMUNON

Birmingham, Alabama, United States and 20 other locations

in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Birmingham, Alabama, United States and 207 other locations

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Fallopian Tube Cancer
Ovarian Cancer
Biological: Pembrolizumab
Drug: Paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Birmingham, Alabama, United States and 226 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems